Kassondra Meyer

An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA -mutated ( gBRCA m) platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Yvette Drew, Maja J.A. de Jonge, Sook Hee Hong et al. · Gynecologic Oncology · 2018 · 130 citations

Gbrca M, Medicine, Gynecology +6

Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Yvette Drew, Bella Kaufman, Susana Banerjee et al. · Annals of Oncology · 2019 · 93 citations · Full text

Medicine, Pathology, Gynecology +6

814MO Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): Initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC)

Yvette Drew, Richard T. Penson, David M. O’Malley et al. · Annals of Oncology · 2020 · 60 citations · Full text

Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study

Yvette Drew, Jae‐Weon Kim, Richard T. Penson et al. · Clinical Cancer Research · 2023 · 59 citations · Full text

Olaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA): An open-label, multicenter, phase 1/2, basket study

Matthew Krebs, Jean‐Pierre Delord, T.R. Jeffry Evans et al. · Lung Cancer · 2023 · 36 citations · Full text